Rousselot Biomedical will supply Gelomics with its gelatin methacryloyl, a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel 3D Tissue Culture System.
Rousselot, a collagen-based solutions provider, and Gelomics, a biotechnology company specializing in integrated 3D cell, organoid, and tissue culture technologies, announced a cobranding partnership on Nov. 16, 2022. Rousselot Biomedical will supply Gelomics with X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel 3D Tissue Culture System.
According to a company press release, gelatin methacryloyl is a biomaterial with tuneability and bioactivity that is used in various functions within engineering, 3D bioprinting, and 3D cell culture applications. Rousselot’s version is considered ultra pure (< 10 endotoxin units/gram) and is the first to be produced under current good manufacturing practice conditions. It will be available in ready-to-use kits in low and high stiffness formulations.
“The broad uptake of modern 3D cell culture techniques in biomedical R&D has been slowed down by a lack of easy-to-use and reproducible biomaterials that enable cells to grow and behave in a physiological manner,” said Christoph Meinert, CEO, Gelomics, in the press release. “We are pleased to partner with Rousselot Biomedical to overcome these limitations and provide the world’s first, ready-to-use 3D cell culture kits based on Rousselot Biomedical’s X-Pure GelMA.”
Source: Rousselot Biomedical
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 4th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.